VAXIMM AG is a private, clinical stage, Swiss/German biotech developing oral T-cell immunotherapies against cancer. VAXIMM’s technology is based on first in-class oral T-cell activators that can be readily adapted to target a wide range of cancer-related antigens. Lead product candidate, VXM01, is designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly.

VXM01 has orphan designation for the EU and the US for glioma. VAXIMM’s neoantigen program (VXM NEO) is in preclinical development and has shown immune proof of concept; the Company’s platform allows for fast generation and delivery of personalized T-cell vaccines and may overcome key issues with other neoantigen approaches. Additional programs are in preclinical development.


VAXXIMM AG at a glance:


Field of Activity
  • Oncology drug development
  • Oral T-cell immunotherapies
  • Neoantigens
Ownership Structure and Financing
  • Headquartered in Basel, Switzerland
  • Wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, from where the Company’s development activities are run
  • Investors include: BB Biotech Ventures, China Medical System Holdings (CMS), M Ventures, Sunstone Capital, BioMed Partners
  • Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. to evaluate VXM01 with avelumab
  • Collaboration agreement with CMS, granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s oral T-cell immunotherapy programs
Technology VAXIMM’s technology is based on first-in-class oral T-cell activators that can be readily adapted to target a wide range of
cancer-related antigens. The platform is based on the live attenuated bacterial vaccine strain Ty21, which has been administered to millions of people as a prophylactic vaccine to temporarily protect them from typhoid fever. This strain has been proven to be safe and well tolerated. All immunotherapies resulting from this
platform are taken orally by the patient. The platform is suitable for addressing multiple targets with one treatment and can be combined with additional immunotherapies.
Date of Incorporation / Number of Employees 2008 / 10


Dr. Heinz Lubenau – COO


Address Technologiepark Basel
Hochbergerstrasse 60c
4057 Basel
Harrlachweg 2
68163 Mannheim
Telephone/Telefax  +49 621-8359687-0/-99
Web Address
Social media LinkedIn Twitter




Hier kostenfrei für den Newsletter anmelden!